Evaluation of Dual Therapy in Real Life Setting in Treatment-Naive Turkish Patients with HCV Infection: A Multicenter, Retrospective Study

Basit Öğe Kaydı
dc.authoridTuncer Ertem, Gunay/0000-0001-8760-0030
dc.authoridDemirturk, Nese/0000-0002-6186-2494
dc.authoridTulek, Necla/0000-0002-3952-4982
dc.authoridGunal, Ozgur/0000-0002-7744-4123
dc.authoridULCAY, ASIM/0000-0003-0531-0668
dc.authoridUral, Onur/0000-0003-1355-7572
dc.authoridSaltoglu, Nese/0000-0003-4239-9585
dc.contributor.authorGurbuz, Yunus
dc.contributor.authorTulek, Necla Eren
dc.contributor.authorTutuncu, Emin Ediz
dc.contributor.authorKoruk, Suda Tekin
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorDemirturk, Nese
dc.contributor.authorKinikli, Sami
dc.date.accessioned2025-01-27T20:20:39Z
dc.date.available2025-01-27T20:20:39Z
dc.date.issued2016
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.descriptionConference of the Asian-Pacific-Association-for-the-Study-of-the-Liver (APASL) -- MAR 12-15, 2014 -- Brisbane, AUSTRALIA
dc.description.abstractBackground: Before the introduction of direct-acting antivirals in the treatment of chronic hepatitis C patients, the combination of peginterferon alpha and ribavirin was the standard therapy. Observational studies that investigated sustained virological response (SVR) rates by these drugs yielded different outcomes. Aims: The goal of the study was to demonstrate real life data concerning SVR rate achieved by peginterferon alpha plus ribavirin in patients who were treatment-naive. Study Design: A multicenter, retrospective observational study. Methods: The study was conducted retrospectively on 1214 treatment naive-patients, being treated with peginterferon alpha-2a or 2b plus ribavirin in respect of the current guidelines between 2005 and 2013. The patients' data were collected from 22 centers via a standard form, which has been prepared for this study. The data included demographic and clinical characteristics (gender, age, body weight, initial Hepatitis C virus RNA (HCV RNA) level, disease staging) as well as course of treatment (duration of treatment, outcomes, discontinuations and adverse events). Renal insufficiency, decompensated liver disease, history of transplantation, immunosuppressive therapy or autoimmune liver disease were exclusion criteria for the study. Treatment efficacy was assessed according to the patient's demographic characteristics, baseline viral load, genotype, and fibrosis scores. Results: The mean age of the patients was 50.74 (+/- 0.64) years. Most of them were infected with genotype 1 (91.8%). SVR was achieved in 761 (62.7%) patients. SVR rate was 59.1% in genotype 1, 89.4% in genotype 2, 93.8% in genotype 3, and 33.3% in genotype 4 patients. Patients with lower viral load yielded higher SVR (65.8% vs. 58.4%, p=0.09). SVR rates according to histologic severity were found to be 69.3%, 66.3%, 59.9%, 47.3%, and 45.5% in patients with fibrosis stage 0, 1, 2, 3 and 4, respectively. The predictors of SVR were male gender, genotype 2/3, age less than 45 years, low fibrosis stage, low baseline viral load and presence of early virological response. SVR rates to each peginterferon were found to be similar in genotype 1/4 although SVR rates were found to be higher for peginterferon alpha-2b in patients with genotype 2/3. The number of patients who failed to complete treatment due to adverse effects was 33 (2.7%). The number of patients failed to complete treatment due to adverse effects was 33 (2.7%). Conclusion: Our findings showed that the rate of SVR to dual therapy was higher in treatment-naive Turkish patients than that reported in randomized controlled trials. Also peginterferon alpha-2a and alpha-2b were found to be similar in terms of SVR in genotype 1 patients.
dc.description.sponsorshipAsian Pacific Assoc Study Liver
dc.identifier.doi10.5152/balkanmedj.2015.15859
dc.identifier.endpage26
dc.identifier.issn2146-3123
dc.identifier.issn2146-3131
dc.identifier.issue1
dc.identifier.pmid26966614
dc.identifier.scopus2-s2.0-84957806463
dc.identifier.scopusqualityQ1
dc.identifier.startpage18
dc.identifier.urihttps://doi.org/10.5152/balkanmedj.2015.15859
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21775
dc.identifier.volume33
dc.identifier.wosWOS:000370967500005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofBalkan Medical Journal
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectHepatitis C
dc.subjectpeginterferon alpha-2a
dc.subjectpeginterferon alpha-2b
dc.subjectribavirin
dc.subjecttherapy
dc.titleEvaluation of Dual Therapy in Real Life Setting in Treatment-Naive Turkish Patients with HCV Infection: A Multicenter, Retrospective Study
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu